Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
Express Scripts
Chinese Patent Office
Daiichi Sankyo
US Department of Justice

Generated: March 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076823

« Back to Dashboard

NDA 076823 describes LITHIUM CARBONATE, which is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Mylan Pharms Inc, Usl Pharma, Watson Labs, West-ward Pharms Int, Alembic Pharms Ltd, Barr, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Unique Pharm Labs, Pfizer, and Sun Pharm Inds Inc, and is included in twenty-nine NDAs. It is available from thirty-three suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 076823
Ingredient:lithium carbonate
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 076823

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength150MG
Approval Date:Jun 29, 2004TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength300MG
Approval Date:Jun 29, 2004TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength600MG
Approval Date:Jun 29, 2004TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.